Replies to post #186006 on Biotech Values

[DewDiligence]

EXAS extends collaboration with Mayo clinic:

http://finance.yahoo.com/news/exact-sciences-mayo-clinic-extend-120000078.html

Exact Sciences Corp. (EXAS) and Mayo Clinic today announced a five-year extension and expansion of their collaboration, broadening their efforts to develop screening, surveillance and diagnostic tests beyond colorectal cancer to address other diseases within the gastrointestinal tract.

The amended agreement extends the collaboration for five more years with David Ahlquist, M.D., a Mayo Clinic gastroenterologist, and his lab at Mayo Clinic. Exact Sciences will continue to have rights to certain intellectual property, including patents, know-how and new markers.

[DewDiligence]

EXAS -11% on lack of 2015 guidance:

http://finance.yahoo.com/news/exact-sciences-reports-fourth-quarter-123000813.html

“Our priorities in 2015 are to continue to grow our Cologuard business and provide world-class physician and patient engagement, while advancing our product pipeline.”

Investors wanted something more concrete, evidently.